Isonics Corporation Executives Adopt 10b5-1 Trading Plans.

GOLDEN, Colo. -- Isonics Corporation (Nasdaq:ISON) (Frankfurt/FSE:IO9) announced that its CEO, James E. Alexander, and other senior executives have adopted pre-arranged stock trading plans in accordance with guidelines specified under Rule 10b5-1 of the Securities and Exchange Act of 1934. The plans allow management to sell a portion of their personal holdings of Isonics common stock over time as part of a long-term strategy to diversify personal assets.

Rule 10b5-1 of the Securities and Exchange Act of 1934 permits officers and directors of public companies to adopt predetermined written plans for trading specified amounts of company stock. Such plans may only be established when the director or officer is not in possession of material nonpublic information. The plans are designed to minimize the market effect of stock sales by spreading them out over an extended period of time, and to avoid concerns about initiating stock transactions while in possession of material non-public information. All transactions under these plans will be disclosed publicly through Form 144 and Form 4 filings with the Securities and Exchange Commission.

Under the plan put in place for Mr. Alexander in July of this year, he will sell up to 240,000 shares of his total holdings of approximately 2 million shares, at a rate of 20,000 shares per month, at a minimum price of $2.50. The 10b5-1 sales will enable Mr. Alexander, 56, to diversify his personal investment holdings and meet retirement planning goals. Mr. Alexander will remain one of Isonics' largest shareholders. Since founding the company in 1993, Mr. Alexander has sold a total of 200,000 shares of his Isonics stock.

About Isonics Corporation

Isonics Corporation has three business divisions: (1) Isonics Semiconductor, (2) Isonics Life Sciences, and (3) Homeland Security and Defense. Isonics is a world leader in isotopically engineered materials and through its semiconductor division produces isotopically pure silicon-28 chemicals, silicon-on-insulator wafers, wafer reclaim services and test wafers, including 300mm, for the semiconductor industry. Isonics' Life Sciences division markets and sells isotopes to the health care industry for the imaging and treatment of cancer. Stable isotopes can be thought of as ultra pure materials. This high degree of purification provides enhanced properties as compared to natural materials. Our efforts in the Homeland Security segment are nascent at the present time as we proceed to develop further our neutron-based detection technologies. Additional information may be obtained at the Company's Web site at www.isonics.com. Isonics is also listed on the Frankfurt Stock Exchange under the ticker symbol IO9.

Cautionary Statement

Except for historical information contained herein, this document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve estimates, assumptions, known and unknown risks and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein. Further, the Company operates in industries where securities values may be volatile and may be influenced by regulatory and other factors beyond the Company's control. Other important factors that the Company believes might cause such differences are discussed in the risk factors detailed in the Company's most recent 10-KSB and reports subsequently filed with the Securities and Exchange Commission, which include the Company's historical cash flow difficulties, dependence on significant customers, and rapid development of technology, among other risks. In assessing forward-looking statements contained herein, readers are urged to carefully read all cautionary statements contained in the Company's filings with the Securities and Exchange Commission.